

Alicante, 26<sup>th</sup> January 11, 2023

## COMMUNICATION – MARKET NOTICE – FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.2.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter "FacePhi" or "the Company") hereby notifies the following:

On November the 11<sup>th</sup> 2022, the Company published the resolution adopted by the Board about to produce a fourth issuance of 48,076,923 equity warrants convertible into Company' shares for a maximum conversion amount of 2,500,000 euros, the "Equity Warrants NOVEMBER 2022", with Nice & Green being the sole recipient of the issue of the Equity Warrants (NOVEMBER 2022).

Nice & Green, on the 23<sup>rd</sup> January 2023, under the provisions of the investment agreement, notified to the Company and exercised its right to convert 394,104 Equity Warrants (NOVEMBER 2022) for a conversion amount of 1,000,000 euros.

As a result of the foregoing, the Company will be obliged to grant a capital increase title deed, for the amount of 15,765.16 €, to attend those Equity warrants converted. There will be an issue of 394,104 new shares, with an issuing price of 2,5374 euros (issue premium 2,4974 euros plus 0.04 euros of nominal value)

Once the capital increase deed has been granted, the share capital will be € 720,932.8 € represented by 18,023,320 shares, numbered from 1 to 18,023,320, of 0,04 € of nominal value each, of the same class, equal, cumulative, and indivisible.

**After this last exercise by Nice & Green, the Investment Agreement signed between the Company and Nice & Green is terminated, being also cancelled the remaining 46,980,354 Equity warrants remaining.**

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró  
Chairman of the Board of Directors